The MedTech Strategist Innovation Summit DUBLIN 2017 – Apr. 25-27 — Agenda

April 25th - 27th, 2017 The Shelbourne Dublin - Dublin, Ireland

Confirmed Start-Up Presenters (42+ in Total):

AFreeze (Innsbruck, Austria) is a medical device company dedicated to improving the treatment for patients with cardiac arrhythmias. Our products are designed to improve patients’ lives and their health. AFreeze has developed a medical device for treatment of cardiac arrhythmias based on a proprietary cryotechnology (cryo= extreme cold).

Amnis Therapeutics (Or Akiva, Israel) is a bio-med engineering company specializing in developing, manufacturing and marketing of lifesaving endovascular technologies for emergency situations. Our latest technology, the Golden Retriever, now in clinical trials, revolutionizes blood clot retrieval in case of acute ischemic stroke.

ArraVasc (Galway, Ireland) is an early stage peripheral vascular business developing innovative, low profile delivery and access technology systems including two innovative, patented technologies in development – PharmaSkin and also Pirouette Scoring Balloon – both aimed initially at ‘below the knee’ (BTK) unmet clinical needs.

Bendit Technologies (Petach Tikva, Israel) – Founded in 2013, Bendit has revolutionized catheterization procedures by giving interventionalists the ability to remotely navigate to challenging vasculature empowering them to more accurately and more rapidly deliver therapy to diseased targets. From a cancerous liver or a calcified aortic arch of a 70 year old to a brain malformation of a 4 year old child, Bendit’s unique navigational system will bring the doctor to the site faster, with less tools, minimized risks and a higher success rate.

BioModex (Paris, France) – The company’s mission is to enhance clinical training and clinical outcomes thanks to a unique patented technology that brings to the physical world patient’s organ twins from a CT scan.

Cardiatis’ (Isnes, Belgium) Multilayer Flow Modulator platform is a paradigm shift in aneurysms treatment. Based on hemodynamic lamination of blood flow inside the aneurysm, the MFM has demonstrated safe and efficient outcomes in the treatment of complex aortic and cerebral aneurysms and aortic dissections. These untapped markets represent a sales potential of $3bn.

Carena Healthcare (Southampton, United Kingdom) is developing a new generation of 3D printed replacement heart valves with zero foreshortening. It is seeking funding for optimisation of its prototype device and for pre-clinical trials.

Caresyntax (Boston, MA) – caresyntax® inc. is a surgical software solutions provider, based in Boston, MA and Berlin, Germany. caresyntax® workflow optimisation solutions are built and deployed in collaboration with many of the leading vendors in surgical medical device, healthcare IT, and hospital infrastructure fields. Our customer footprint allows us to help optimize workflow in over 10 million surgical procedures each year.

Cologuard Ltd. (Kfar Saba, Israel) is a clinical stage medical device company developing novel and proprietary technology for colorectal surgery aiming to prevent the profound clinical and economic pains associated with anastomotic leaks and diverting colonic stomas.

Contextflow (Vienna, Austria) uses machine learning to analyze large medical image data and connected facts and revolutionize the information search process of Radiologists using 3D image search.

DirectSens (Wien, Austria) has developed next-generation biosensors enabling the precise and robust detection of sugars including glucose or lactose in body fluids and agri-food samples for continuous and single use.

Exactus Inc. (EXDI; Richmond, VA) is in the process of developing the first handheld, Point-of-Care tests that measure proteolytic enzymes in the blood using our patented Electoactive Polymer detection platform. Our first products will measure [1]  fibrinolytic activity, a key component in maintenance of hemostasis for use in the ER and OR surgical setting  and [2] collagenase activity for us as an at-home test for cancer recurrence and metastasis. Using only a drop of blood our devices can deliver results in as little as 30 seconds, eliminating the need to send patient samples to a lab and wait for test results.

Eye Tech Care SA (Paris, France) has developed a proprietary technology to treat glaucoma non-invasively with focused ultrasound. The device consists of a controller and a disposable eye probe. It is CE marked and clinical data on over 250 patients have been published demonstrating efficacy and excellent tolerance of the procedure. Market access in further countries is under way.

Glucorecs’ (Mountain View, CA) patented Non-Invasive Glucose Sensing technology, the personal portable device, GluFit™, is validated in preclinical human trials.

GraftWorx (Menlo Park, CA) – Medicine today is characterized by clinicians looking retrospectively at diagnostic imaging and laboratory data, which results in expensive, reactionary procedures. GraftWorx is turning the Internet of Things into the Internet of the Body by enabling current “dumb” cardiovascular implants to become “smart.” We then leverage our cloud platform to alert clinicians of potential disasters. Our first product (currently in pre-clinical trials) will save 40,000 amputations in the US each year.


Hemovent GmbH (Aachen, Germany) is an emerging medical device company that has developed disruptive technology: the world’s smallest and first self-contained fully portable Extra Corporeal Membrane Oxygenation (ECMO) system that supports or replaces heart and lung function in the event of cardiac and respiratory failure.

ID-NEST Medical (Alsace, France) is developing the first fully compliant branched endograft system. Our innovative ‘click-connect’ technology brings a long-term patency solution to some vascular indications that are ill-treated at the moment. Our Venous range is targeting Compressed Illiac Veins (May-Thurner Syndrom) that affects millions in all countries. The Arterial version will dramatically improve the treatment of Aortic Arch Aneurysms, currently a delicate operation to manage.

InfanDx AG (Cologne, Germany) is developing a new generation of diagnostic tests for the care of neonates. Primary focus is the early identification of newborns suffering from critical oxygen supply deficit during birth (Asphyxia), a major cause for brain injury often followed by life long disabilitation. Nowadays, treatment that reduces morbidity is available. Unfortunately, it requires very early application after birth. Currently no test system is available that meets this crucial demand. InfanDx closes this diagnostic gap by carrying such test system through clinical development until it is available for routine use in the hospital.

Jupiter Diagnostics (London, UK) uses two proprietary technologies which we bolt on to existing lab chemistries allowing us to miniaturise the lab and drive down the cost of testing.

Kejako (Geneva, Switzerland), founded in March 2015, is developing minimally invasive surgical solution for demanding midlifers wanting to keep quality of life by compensating loss of visual accommodation. We address the ophthalmology field with an anti-aging mindset in order to treat presbyopia. We delay the need for reading glasses without compromising the quality of vision, unlike other existing surgical solutions. Our core competences are numerical simulation and medical device development.

Life Care Medical Devices (New Smyrna Beach, FL) is an innovative medical device company with two FDA-approved devices currently being sold. One device, LapCap2, which is also CE marked, lifts the abdominal wall to facilitate safer and easier laparoscopic access. Our second device utilizes RF and electro-magnetic induction to deliver therapeutic heat to muscle tissues. Our pipeline for intended treatment ranges from aesthetics, wrinkles and vaginal tightening to addressing incontinence and bio-adhesion.

LimFlow (Paris, France) was founded by the European medical device accelerator MD Start in 2012 and has developed the world’s first system for creating a percutaneous Deep Vein Arterialization of the foot for the treatment of End Stage Critical Limb Ischemia. This is the first ever successfully completed fully endovascular approach to achieving venous arterialization of the leg.

Loci Orthopaedics (Galway, Ireland; formerly known as AltSurgical) has developed InDx – a novel orthopaedic implant for the treatment of thumb base arthritis. This is a common condition, affecting over 5% of the general population. The InDx implant is the only implant that can fully mimic the natural but complex motions of this joint. The implant is also easier to insert and less invasive than any currently available surgical treatment option for this condition.

Mainstay Medical International plc (Dublin, Ireland) is a medical device company focused on bringing to market an innovative implantable neurostimulation system, ReActiv8®, for people with disabling Chronic Low Back Pain (CLBP). The Company is headquartered in Dublin, Ireland. It has subsidiaries operating in Ireland, the United States, Australia and Germany, and its ordinary shares are admitted to trading on Euronext Paris (MSTY.PA) and the ESM of the Irish Stock Exchange (MSTY.IE).

MC Technology (Hargelsberg, Austria) has developed TheraMon®, a tiny state-of-the-art electronic microsensor (ASIC – application specific integrated circuit) plus dedicated hard- and software to deliver precise patient compliance data on the real use of dental appliances for orthodontics and snoring appliances. These can be used to treat serious conditions of sleep apnea, medical aids for orthopedics (e.g. scoliosis jackets), or can even be used to monitor thermo sensitive logistics (e.g. human blood samples).

Med Alliance (Geneva, Switzerland) –  Medical devices for the successful treatment of coronary and peripheral artery disease.

Miracor Medical Systems’ (Vienna, Austria) PiCSOAMI Therapy seeks to increase blood flow to the affected heart tissue, thereby improving the overall heart function after an Acute Myocardial Infarction (AMI). Recent Pre-Clinical and Clinical Studies have successfully demonstrated the positive effects of PiCSO on myocardial function and infarct size in acute heart attack patients. The PiCSOAMI Impulse System consists of a driving console and associated catheters and offers the Heart Team new options to improve clinical outcome in Acute Myocardial Infarction patients.

MMI Srl (Pisa, Italy) is a robotics startup dedicated to advancing the future of micro-surgery. MMI’s proprietary robotic platform and wristed micro-instruments simplify, among others, reconstruction procedures after traumatic injuries as well as after tumor removal in breast, head and bones. The Company’s mission is to help more surgeons around the world to offer more advanced procedures, while reducing costs for patients, hospitals and for the society in general.

Momentum BioScience (Cardiff, United Kingdom) has developed the Cognitor, a product that allows reporting of all blood cultures, negative and positive, within 20 hrs., improving patient health and reducing costs.

OrthoSera (Krems an der Donau, Austria) has developed blood-serum based technologies that are capable of regeneration of bone and joint tissue through the activation of the patient’s own stem cells.

PerfAction Technologies (Rehovot, Israel) – Jet Volumetric Remodeling (JVR) powers EnerJet™. This proprietary technology simultaneously delivers kinetic energy and a healing compound enabling even spread of the compound and controlled deep micro-trauma profile for dermal thickening and scar remodeling.

Ponce De Leon Pharmaceuticals (Dublin, Ireland) is developing a product formulation aimed at postponing the onset of human frailty, and the extension of human healthspan, the healthy years of living.  The company has partnered with The Buck Institute for Research on Aging, and currently is testing its product in animals, with impressive early results.

Promaxo, Inc. (Rockville, MD) is a medical device company developing and commercializing an office-based and cost effective MRI with cellular level spatial resolution, real time biopsy and treatment tools, and automated software for tissue characterization. The Company’s current focus is on addressing the needs of the prostate cancer market.

ProVerum Medical (Dublin, Ireland) has developed a novel, non-invasive medical device to treat symptomatic Benign Prostatic Hyperplasia (BPH), inserted as a day case in a Urologist’s office.

Pulmostics (Newbury Park, CA) has harnessed the power of, breath analysis, an emerging science that carries the potential to re-invent the medical point-of-care diagnostic ecosystem. Our solutions have demonstrated unprecedented accuracy in detecting and analyzing trace biomarkers present in human breath, leading to the real time diagnosis of deadly acute and chronic diseases.

RSP Systems A/S (Odense, Denmark) is dedicated to improving the health and quality of life of people worldwide through its unique and patented solution for non-invasive diagnostics. The first targeted application is a product line of noninvasive glucose monitors, which will provide diabetic patients with a convenient, pain free alternative to the current invasive solutions.

Sensimed AG (Lausanne, Switzerland): The SENSIMED Triggerfish® is a unique system composed of a soft sensing contact lens which captures spontaneous circumferential changes at the corneoscleral area over 24 hours. This technology is currently used by eye doctors to further improve glaucoma management in patients at risk of progression. This safe and sensitive system is non-invasive and practical.

Spirosure (Pleasanton, CA) is a Silicon Valley-based, private medtech company with novel technology that allows physicians, patients and payers to manage asthma through proprietary devices that non-invasively measure a biomarker of airway inflammation – called FeNO (Fractional Exhaled Nitric Oxide).  Spirosure accomplishes this through the use of a, first-of-its-kind, solid-state sensor housed in specialized devices used in both physicians’ clinics and patients’ homes.  This system also has a software component or proprietary “digital ecosystem” which connects to other respiratory devices and pulls environmental information (i.e. pollen count, pollution index, air quality, etc.) that help uncover insights leading to better clinical decisions through “pattern recognition” and “pattern management.”

SurePulse Medical (Derby, United Kingdom) has developed highly accurate vital sign monitoring technology, with a first product targeted at helping babies who need resuscitation at birth. Our sensor technology is integrated into a specially designed newborn hat for rapid and reliable acquisition of heart rate.

The company aims to become the gold standard in wearable vital sign monitoring, combining clinical grade accuracy with appropriate product design.

SurgaColl Technologies Ltd. (Dublin, Ireland) develops and manufactures innovative, regenerative orthopaedic implants based on a platform of technologies developed at the Royal College of Surgeons of Ireland which enhances the natural healing process in the repair of bone and cartilage tissue defects.

Chondrocoll is a patented, cell-free, three-layer implant for restoring  damaged cartilage, and meets a large unmet need in early-stage knee cartilage repair. Regulatory approval in Europe is imminent. HydroxyColl is a highly innovative next-generation bone graft which shows great promise in a $2bn market following extensive preclinical trials. The product is now approved in Europe and in early clinical usage.

TransVerse Medical (Golden, CO) is developing the POINT-GUARD™, the first and only cerebral embolic protection device with Dynamic Double-Edge Sealing.  The Seal adapts and conforms to complex arch anatomy by maintaining contact with the aorta, enabling maximum great arch vessel coverage, and directing debris-laden blood through the filter. Thus, safeguarding the brain to provide complete embolic protection for addressing the unmet clinical need to keep debris out of the cerebral arteries and protect all territories of the brain during left heart procedures. Initial procedure focus is Transcatheter Aortic Valve Replacement (TAVR).  During TAVR, procedural stroke is documented as high as 9.1% and clinically-significant debris is present in 99% of patients.1

 1 SENTINEL Trial, Control Arm data, JACC, Nov 2016

Woven Orthopedic Technologies (Manchester, CT) is a medical device business that designs and develops orthopedic technologies to treat the rapidly aging global population affected by orthopedic conditions. Our premiere technology addresses the #1 problem with the #1 technology used in orthopedics today by enhancing screw fixation in patients who receive treatment for fractures.